Thermo Fisher Scientific Sees Unusually High Options Volume (NYSE:TMO)

Tuesday, April 13, 2021 | MarketBeat

Thermo Fisher Scientific Inc. (NYSE:TMO) saw some unusual options trading activity on Tuesday. Stock traders purchased 6,686 call options on the company. This represents an increase of 80% compared to the typical volume of 3,714 call options.

Thermo Fisher Scientific stock traded up $8.47 during midday trading on Tuesday, hitting $484.45. The stock had a trading volume of 95,392 shares, compared to its average volume of 1,808,347. The firm's fifty day moving average is $455.05 and its two-hundred day moving average is $472.13. The company has a market capitalization of $190.77 billion, a PE ratio of 39.01, a P/E/G ratio of 1.40 and a beta of 0.85. Thermo Fisher Scientific has a 52-week low of $309.18 and a 52-week high of $532.57. The company has a current ratio of 2.93, a quick ratio of 2.31 and a debt-to-equity ratio of 0.66.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Sunday, January 31st. The medical research company reported $7.09 EPS for the quarter, beating analysts' consensus estimates of $6.56 by $0.53. Thermo Fisher Scientific had a return on equity of 21.35% and a net margin of 17.12%. The firm had revenue of $10.55 billion during the quarter, compared to the consensus estimate of $9.53 billion. During the same period in the prior year, the company earned $3.55 EPS. The company's quarterly revenue was up 54.5% compared to the same quarter last year. As a group, equities research analysts predict that Thermo Fisher Scientific will post 19.03 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 16th. Shareholders of record on Tuesday, March 16th will be issued a $0.26 dividend. This represents a $1.04 annualized dividend and a yield of 0.21%. The ex-dividend date of this dividend is Monday, March 15th. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.22. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 8.42%.

Institutional investors have recently added to or reduced their stakes in the stock. Annapolis Financial Services LLC purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $26,000. ShoreHaven Wealth Partners LLC purchased a new stake in Thermo Fisher Scientific during the 4th quarter worth about $28,000. Dimension Capital Management LLC purchased a new position in shares of Thermo Fisher Scientific in the 3rd quarter valued at about $31,000. Larson Financial Group LLC grew its stake in Thermo Fisher Scientific by 38.5% during the 4th quarter. Larson Financial Group LLC now owns 72 shares of the medical research company's stock worth $34,000 after buying an additional 20 shares during the last quarter. Finally, Oder Investment Management LLC acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth approximately $34,000. 87.17% of the stock is owned by hedge funds and other institutional investors.

TMO has been the subject of several research reports. Morgan Stanley increased their target price on shares of Thermo Fisher Scientific from $535.00 to $575.00 and gave the company an "overweight" rating in a research note on Tuesday, February 2nd. BTIG Research boosted their price objective on shares of Thermo Fisher Scientific from $540.00 to $590.00 and gave the company a "buy" rating in a research report on Wednesday, February 3rd. KeyCorp raised shares of Thermo Fisher Scientific from a "sector weight" rating to an "overweight" rating and set a $520.00 price objective on the stock in a research report on Wednesday, March 24th. Zacks Investment Research lowered shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating and set a $488.00 price target on the stock. in a research note on Tuesday, December 22nd. Finally, Stifel Nicolaus boosted their price objective on shares of Thermo Fisher Scientific from $530.00 to $600.00 and gave the stock a "buy" rating in a research note on Tuesday, February 2nd. Four equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company's stock. Thermo Fisher Scientific has a consensus rating of "Buy" and an average target price of $524.45.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Featured Article: What does earnings per share mean?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Featured Article: Growth Stocks, What They Are, What They Are Not

7 Infrastructure Stocks That May Help Rebuild America

Despite their disagreements (real or imagined) on almost everything, Democrats and Republicans alike love infrastructure projects. These are easy wins for Congressional leaders seeking re-election. And they typically spur job creation, which contributes to economic growth.

With that in mind, it’s ironic that, in the last four years, the United States Congress did not pass an infrastructure bill.

Nevertheless, even with (and maybe because of) the gridlock that looks to be in the country’s future, the infrastructure looks to be on the front burner again. The economic recovery is still far from complete. Unfortunately, neither are America’s roads, energy grid, telecommunications systems, and the like. That means that it would seem like a good policy for a Biden administration to look at an infrastructure bill.

Biden will be under pressure to endorse the $1.5 trillion infrastructure package that the Democrat-controlled House of Representatives passed in July. But the package may need to be tweaked a bit since it currently includes climate change initiatives that have kept the bill from advancing through the Senate.

However, it appears that the economy will need some significant juice after whatever this winter brings in terms of the virus. And if calmer heads prevail (we can always hope), there may be a major infrastructure bill to stimulate job creation. And we’ve identified seven stocks that should bear watching if this comes to pass.

View the "7 Infrastructure Stocks That May Help Rebuild America".

Free Email Newsletter

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.